Novus Therapeutics (NVUS) vs. Alimera Sciences (ALIM) Head to Head Contrast

Novus Therapeutics (NASDAQ: NVUS) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Novus Therapeutics and Alimera Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novus Therapeutics N/A -156.99% -140.33%
Alimera Sciences -55.29% N/A -28.43%

Earnings and Valuation

This table compares Novus Therapeutics and Alimera Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novus Therapeutics N/A N/A -$37.95 million N/A N/A
Alimera Sciences $34.33 million 2.66 -$33.17 million ($0.31) -4.26

Alimera Sciences has higher revenue and earnings than Novus Therapeutics.

Institutional and Insider Ownership

40.8% of Novus Therapeutics shares are held by institutional investors. Comparatively, 41.8% of Alimera Sciences shares are held by institutional investors. 5.2% of Novus Therapeutics shares are held by insiders. Comparatively, 14.7% of Alimera Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Novus Therapeutics and Alimera Sciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novus Therapeutics 0 0 0 0 N/A
Alimera Sciences 0 0 3 0 3.00

Alimera Sciences has a consensus price target of $4.00, indicating a potential upside of 203.03%. Given Alimera Sciences’ higher possible upside, analysts plainly believe Alimera Sciences is more favorable than Novus Therapeutics.

Volatility and Risk

Novus Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.

Summary

Alimera Sciences beats Novus Therapeutics on 9 of the 10 factors compared between the two stocks.

About Novus Therapeutics

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

About Alimera Sciences

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply